Item Type | Name |
Concept
|
Combined Modality Therapy
|
Concept
|
Drug Therapy
|
Concept
|
Drug Therapy, Combination
|
Concept
|
Embolization, Therapeutic
|
Concept
|
Chemoembolization, Therapeutic
|
Concept
|
Salvage Therapy
|
Concept
|
Treatment Outcome
|
Concept
|
Molecular Targeted Therapy
|
Concept
|
Treatment Failure
|
Concept
|
Genetic Therapy
|
Concept
|
Neoadjuvant Therapy
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
Academic Article
|
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
|
Academic Article
|
Small cell lung cancer: from molecular biology to novel therapeutics.
|
Academic Article
|
Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
|
Academic Article
|
Targeting c-Kit mutations: basic science to novel therapies.
|
Academic Article
|
Phase II study of imatinib in patients with small cell lung cancer.
|
Academic Article
|
Therapeutic targeting of the receptor tyrosine kinase Met.
|
Academic Article
|
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
|
Academic Article
|
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
|
Academic Article
|
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
|
Academic Article
|
Novel therapies in lung cancer.
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
Academic Article
|
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
|
Academic Article
|
c-Met: structure, functions and potential for therapeutic inhibition.
|
Academic Article
|
Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors.
|
Academic Article
|
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
Academic Article
|
MET as a target for treatment of chest tumors.
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
Academic Article
|
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
|
Academic Article
|
Biology and novel therapeutics for neuroendocrine tumors of the lung.
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
Academic Article
|
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity.
|
Academic Article
|
MET pathway as a therapeutic target.
|
Academic Article
|
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
|
Academic Article
|
Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers.
|
Academic Article
|
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.
|
Academic Article
|
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
Academic Article
|
Mind-mapping for lung cancer: towards a personalized therapeutics approach.
|
Academic Article
|
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).
|
Academic Article
|
Therapeutic targeting of receptor tyrosine kinases in lung cancer.
|
Academic Article
|
Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer.
|
Academic Article
|
Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
|
Academic Article
|
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
|
Academic Article
|
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
Academic Article
|
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.
|
Academic Article
|
c-Met is a potentially new therapeutic target for treatment of human melanoma.
|
Academic Article
|
MET molecular mechanisms and therapies in lung cancer.
|
Academic Article
|
Personalized treatment of lung cancer.
|
Academic Article
|
An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer.
|
Academic Article
|
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
|
Academic Article
|
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
Academic Article
|
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
|
Academic Article
|
Key signaling pathways and targets in lung cancer therapy.
|
Academic Article
|
Novel targets for therapeutic agents in small cell lung cancer.
|
Academic Article
|
The role of EGFR inhibition in the treatment of non-small cell lung cancer.
|
Academic Article
|
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
Academic Article
|
Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
|
Academic Article
|
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
|
Academic Article
|
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma.
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
Academic Article
|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
|
Academic Article
|
Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases.
|
Academic Article
|
EphB4 as a therapeutic target in mesothelioma.
|
Academic Article
|
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
|
Academic Article
|
Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
|
Academic Article
|
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
|
Academic Article
|
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.
|
Academic Article
|
MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
|
Academic Article
|
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
|
Academic Article
|
Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches.
|
Academic Article
|
Mitochondrial dynamics: biology and therapy in lung cancer.
|
Academic Article
|
O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer.
|
Academic Article
|
Molecular pathways and therapeutic targets in lung cancer.
|
Academic Article
|
Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.
|
Academic Article
|
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.
|
Academic Article
|
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
|
Academic Article
|
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.
|
Academic Article
|
A new hope for precision medicine.
|
Academic Article
|
Biomarkers in lung cancer: from early detection to novel therapeutics and decision making.
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
Academic Article
|
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
|
Academic Article
|
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
|
Academic Article
|
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
|
Academic Article
|
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
|
Academic Article
|
Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.
|
Academic Article
|
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
|
Academic Article
|
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
|
Academic Article
|
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
|
Academic Article
|
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
|
Academic Article
|
Systemic therapies in the treatment of non-small-cell lung cancer brain metastases.
|
Academic Article
|
Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.
|
Academic Article
|
Tumor Heterogeneity and Therapeutic Resistance.
|
Academic Article
|
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.
|
Academic Article
|
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
|
Academic Article
|
FAK and paxillin, two potential targets in pancreatic cancer.
|
Academic Article
|
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
|
Academic Article
|
The MET axis as a therapeutic target.
|
Academic Article
|
Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.
|
Academic Article
|
Genomic mutation-driven metastatic breast cancer therapy: a single center experience.
|
Academic Article
|
Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC).
|
Academic Article
|
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
|
Academic Article
|
Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.
|
Academic Article
|
Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
|
Academic Article
|
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy.
|
Academic Article
|
Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.
|
Academic Article
|
Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
|
Academic Article
|
Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience.
|
Academic Article
|
EphB4: A promising target for upper aerodigestive malignancies.
|
Academic Article
|
Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.
|
Academic Article
|
Managing Patients With Relapsed Small-Cell Lung Cancer.
|
Academic Article
|
Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention.
|
Academic Article
|
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
|
Academic Article
|
Untying the gordion knot of targeting MET in cancer.
|
Academic Article
|
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
|
Academic Article
|
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.
|
Academic Article
|
Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.
|
Academic Article
|
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
|
Academic Article
|
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
|
Academic Article
|
Targeted Therapies in Non-small-Cell Lung Cancer.
|
Academic Article
|
Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.
|
Academic Article
|
Notch signaling in breast cancer: From pathway analysis to therapy.
|
Academic Article
|
The Mitochondrion as an Emerging Therapeutic Target in Cancer.
|
Academic Article
|
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.
|
Academic Article
|
Therapeutic targeting of miRNA-216b in cancer.
|
Academic Article
|
Targeting RLIP with CRISPR/Cas9 controls tumor growth.
|
Academic Article
|
Opportunities for improving cancer treatment using systems biology.
|
Academic Article
|
The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy.
|
Academic Article
|
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.
|
Academic Article
|
MET receptor in oncology: From biomarker to therapeutic target.
|
Academic Article
|
Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research.
|
Academic Article
|
The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States.
|
Academic Article
|
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
|
Academic Article
|
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence.
|
Academic Article
|
Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy.
|
Academic Article
|
Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP.
|
Academic Article
|
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
|
Academic Article
|
Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
|
Academic Article
|
Disparate outcomes in nonsmall cell lung cancer by immigration status.
|
Academic Article
|
RNA-based therapies: A cog in the wheel of lung cancer defense.
|
Academic Article
|
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
|
Academic Article
|
Targeting the mercapturic acid pathway for the treatment of melanoma.
|
Academic Article
|
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
Academic Article
|
Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
|
Academic Article
|
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
|
Academic Article
|
Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment.
|
Academic Article
|
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
|
Academic Article
|
ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?
|
Academic Article
|
Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients.
|
Academic Article
|
Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma.
|
Academic Article
|
Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
|
Academic Article
|
Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
|
Academic Article
|
Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics.
|
Academic Article
|
An Updated Review on Radiation Treatment Management in Thymus Cancers.
|
Academic Article
|
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
|
Concept
|
Time-to-Treatment
|
Grant
|
Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer
|
Grant
|
Role of Paxillin in Lung Cancer
|
Grant
|
MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
|
Grant
|
Role of c-Met in SCLC and Potential for Novel Therapy
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|
Grant
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|
Academic Article
|
LSD1-targeted therapy-a multi-purpose key to unlock immunotherapy in small cell lung cancer.
|
Academic Article
|
The innate effects of plant secondary metabolites in preclusion of gynecologic cancers: Inflammatory response and therapeutic action.
|
Academic Article
|
Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
|
Academic Article
|
Phase II Trial of Lung Chemoembolization.
|
Academic Article
|
Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.
|
Grant
|
Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC
|
Academic Article
|
Emerging biomarkers and molecular targets for precision medicine in cervical cancer.
|
Academic Article
|
Nanoengineering Solutions for Cancer Therapy: Bridging the Gap between Clinical Practice and Translational Research.
|
Academic Article
|
Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies.
|
Academic Article
|
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells.
|
Academic Article
|
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies.
|
Academic Article
|
Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential.
|
Academic Article
|
RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.
|